An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.

Phase 2 Unknown 139 enrolled Fudan University

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase II, open-label, randomized controlled umbrella trial evaluating the efficacy and safety of multiple targeted treatment in patients with metastaticTNBC.

Timeline

Start: 2020-07-28
Primary completion: 2023-05-31
Completion: 2024-12-31

Publications

Fan L, Wang ZH, Ma LX, Wu SY, Wu J, Yu KD, Sui XY, Xu Y, Liu XY, Chen L, Zhang WJ, Jin X, Xiao Q, Shui RH, Xiao Y, Wang H, Yang YS, Huang XY, Cao AY, Li JJ, Di GH, Liu GY, Yang WT, Hu X, Xia Y, Liang QN, Jiang YZ, Shao ZM. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. Lancet Oncol. 2024 Feb;25(2):184-197. doi: 10.1016/S1470-2045(23)00579-X. Epub 2024 Jan 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Everolimus	Small molecule	10 mg	Oral
Subject	Famitinib	Small molecule	20 mg	Oral
Subject	Famitinib	Small molecule	200 mg	Intravenous
Subject	Paclitaxel	Small molecule	100 mg/m2	Intravenous
Subject	Pyrotinib	Small molecule	400 mg	Oral
Background	Capecitabine	Small molecule	1000 mg/m2	Oral

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.

Summary

Timeline

Publications

Drugs

Indications